FDANonrulemakingFDA-2026-D-1257

Who commented on this docket

Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing; Draft Guidance for Industry; Availability

12 organizations filed 12 public comments on Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing; Draft Guidance for Industry; Availability, at the Food and Drug Administration. The comment window closed 19d ago.

Organizations
12
Comments
12
RIN
Comment window
closed 19d ago

Commenters (12)

  • Alliance for mRNA Medicinestrade assoc.
    1 filing · confidence 85%
  • American Society of Gene & Cell Therapytrade assoc.
    1 filing · confidence 85%
  • Cystic Fibrosis Foundationtrade assoc.
    1 filing · confidence 85%
  • eXmoor Pharma Concepts Ltdunverified attribution
    1 filing · confidence 70%
  • International Society for Stem Cell Researchtrade assoc.
    1 filing · confidence 85%
  • Parenteral Drug Associationtrade assoc.
    1 filing · confidence 97%
  • Pediatric Inclusion Alliancetrade assoc.
    1 filing · confidence 85%
  • Personalized Medicine Coalitiontrade assoc.
    1 filing · confidence 85%
  • Sana Biotechnology Inc.unverified attribution
    1 filing · confidence 70%
  • The Alliance for Regenerative Medicinetrade assoc.
    1 filing · confidence 85%
  • The Cure Coalitiontrade assoc.
    1 filing · confidence 85%
  • University of Pennsylvania Health Systemunverified attribution
    1 filing · confidence 70%
View this docket on regulations.gov →

Attribution is name-based and imperfect. regulations.gov data is public record.